Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  SpineGuard    ALSGD   FR0011464452

SPINEGUARD

(ALSGD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

16 October 2020 – 10h45 CET : SpineGuard morning note by BioStrategic Research (in english) (Download PDF)

10/16/2020 | 05:00am EST

Morning Note - 16th October 2020

SPINEGUARD

France - Medtech

Q3: a satisfactory recovery in activity

BUY

x

Rebound after a weak Q2

Fair value (EUR)

0.85

Safeguard procedure: hearing scheduled for October 21st

Price (EUR)

0.181

A second wave whose impact is delicate to quantify

Upside/down side

+ 370%

Rescheduling of surgeries supported Q3 sales

SpineGuard published last night its Q3 turnover which came out at EUR1.33m, down -23% compared to Q3 2019 (-20% at constant exchange rates). Sales nevertheless increased by + 47% compared to Q2, which was severely impacted by the health crisis (postponement of numerous interventions to free up capacity in intensive care units and recovery rooms). Over the period, the group sold 1,424 Pediguard units against 886 in Q2 2020, highlighting the reprogramming of spine surgeries. Activity outside the US, particularly in France and Germany, was strong (+ 10% sales vs. Q3 2019 and

  • 152% of units sold vs. Q2). The group has not seen any sales in China (countries with significant stocks), a situation which has a positive impact on the ASP (Average Selling Price) which we estimate to be outside the US at EUR481 (vs. EUR351 in fiscal year 2019). The situation in the US is more complex with a somewhat weaker than expected recovery (+ 24% units sold compared to Q2). While the number of overdue patients has not decreased during the confinement period, the fear of contracting the virus in hospital may represent a barrier to some patients' decision to undergo surgery, but the major impact seems to lie in the lack of visibility for certain households (loss of employment and therefore loss of the healthcare insurance). After a complex period, management plans to strengthen its commercial actions in the US to boost sales (layoffs in the sector offer opportunities to recruit good salespeople).

Lionel Labourdette, PhD, MBA

lionel@biostrategic-research.com+33 617 965 019

Stock data (2020-10-15)

ISIN

FR0011464452

Ticker

ALSGD.PA

Price (EUR)

0.181

Market capitalisation (EURm)

3.8

Free float (%) est.

85,0

Floating capitalisation (EURm)

3.3

Number of shares (,000)

20,848

Average daily volume (3 m)

122,427

12m performance

0,40

0,30

0,20

0,10

0,00

16/12/19

16/06/20

16/10/19

16/02/20

16/04/20

16/08/20

16/10/20

ALSGD

ALSGD rel to CAC Small & Mid 190

What to expect from the upcoming hearing?

SpineGuard is due to present its plan to the Commercial Court of Créteil next week. It is very likely that the rescheduling of the debt will be recorded in order to give the group better visibility to repay its creditors. It should be kept in mind that operational balance has almost been reached and the realistic development plan (sales growth, partnerships) must be supported by postponing loan repayment deadlines.

Valuation and rating

The released figures are reassuring. The dynamics in the US could be better but the situation can change very quickly in this area. The current question mark is the impact of the second wave which is affecting Europe and may cause the postponement of some surgeries. However, the postponement cannot go on forever. The stock price is still decorrelated from the value and potential of the technology. We therefore remain positive on the dossier.

Next communication:FY revenues (end of January 2021, date to be defined)

Change (%)

1 m

3 m

12m

Absolute

-1.1%

-4.5%

-25.8%

Rel. to CAC SM190

1.5%

-4.9%

-16.1%

Rel. to Next Biotech

-8.6%

8.4%

-45.4%

Financials (31/12)

EURm

2019

2020E

2021E

2022E

Sales

6.8

5.4

7.9

10.0

EBITDA

-0.1

-0.8

0.5

1.1

EBIT

-0.4

-1.0

0.2

0.8

Net income

-0.7

-1.7

-0.1

0.6

EPS (EUR)

0.0

-0.1

0.0

0.0

Net debt

4.7

4.9

3.1

4.4

Key ratios

2019

2020E

2021E

2022E

EV/Sales

1.1x

1.6x

0.9x

0.8x

EV/EBITDA

na

na

12.7x

7.3x

EV/EBIT

na

na

27.7x

9.9x

PER

na

na

na

6.3x

ROIC

-9%

na

5%

17%

ROE

12%

30%

2%

-6%

EV/IC

1.5x

1.8x

1.4x

1.7x

Gearing

-84%

-85%

-49%

-43%

The issuer and Biostrategic Partners have agreed that Biostrategic Partners will produce and disseminate investment research as a service

1

Profit and Loss

As of 31/12 (EURm)

2015

2016

2017

2018

2019

2020E

2021E

2022E

Sales

6.35

7.46

8.17

7.58

6.83

5.37

7.95

10.00

Change n-1

43.1%

17.6%

9.5%

-7.3%

-9.9%

-21.4%

48.0%

25.8%

Other revenues

-

-

-

-

-

-

-

-

Total revenues

6.35

7.46

8.17

7.58

6.83

5.37

7.95

10.00

Gross margin

5.36

6.35

6.95

6.55

5.77

4.59

7.01

8.89

EBITDA

-3.73

-3.31

-2.66

-0.86

-0.14

-0.76

0.54

1.13

Change n-1

12%

11%

20%

68%

84%

-460%

171%

-108%

Depreciation & amortisation

0.26

0.33

0.31

0.26

0.30

0.29

0.29

0.30

Goodwill

-

-

-

-

-

-

-

-

EBIT

-3.97

-3.63

-2.96

-1.11

-0.43

-1.05

0.25

0.83

Change n-1

11%

9%

18%

63%

61%

-143%

124%

-232%

Net financial income

0.10

-0.54

-1.16

-1.21

-0.64

-0.69

-0.36

-0.23

Minorities

-

-

-

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

Net profit before tax

-3.88

-4.18

-4.13

-2.32

-1.07

-1.74

-0.11

0.60

Tax

-

-

-

-0.02

0.39

-

-

-

Net in come

-3.88

-4.18

-4.13

-2.33

-0.69

-1.74

-0.11

0.60

Change n-1

15%

-8%

1%

43%

71%

-154%

94%

646%

EPS

-0.77

-0.82

-0.72

-0.34

-0.05

-0.10

-0.01

0.03

EPS fully diluted

-0.77

-0.75

-0.68

-0.38

-0.05

-0.09

-0.01

0.03

Gross margin (% of sales)

84.5%

85.1%

85.1%

86.5%

84.5%

85.5%

88.1%

88.9%

EBITDA (% of sales)

na

na

na

na

na

na

7%

11%

EBIT (% of sales)

na

na

na

na

na

na

3%

8%

Net margin (% of sales)

na

na

na

na

na

na

na

6%

Cash Flow statement

Au 31/12 (MEUR)

2015

2016

2017

2018

2019

2020E

2021E

2022E

Net income

-3.88

-4.18

-4.13

-2.33

-0.69

-1.74

-0.11

0.60

Depreciation and amortisation

0.26

0.33

0.31

0.26

0.30

0.29

0.29

0.30

Goodwill

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Change in WCR

0.53

-1.01

0.26

-0.08

0.27

-0.60

-0.37

-0.14

Others

0.50

0.83

1.05

1.49

0.71

1.01

0.67

0.54

Cash-flow from operations

-2.60

-4.03

-2.51

-0.67

0.60

-1.05

0.49

1.30

Capex

-0.20

-0.06

-0.05

-0.05

-0.08

-0.08

-0.08

-0.08

Free cash flow

-2.80

-4.09

-2.56

-0.72

0.52

-1.13

0.41

1.22

Acquisitions

-0.37

-0.09

-

-

-0.15

-

-

-

Divestments

-

0.01

-

-

-

-

-

-

Dividends

-

-

-

-

-

-

-

-

Capital increase

2.64

0.42

2.21

1.68

1.75

-

-

-

Financing (bank and others)

2.76

2.87

0.01

4.64

0.22

-

-

-

Others

-1.51

-0.54

-0.26

-5.73

-1.54

-

-2.36

-2.53

Change in cash over the period

0.72

-1.42

-0.61

-0.13

0.80

-1.13

-1.96

-1.31

Opening cash position

2.51

3.23

1.80

1.19

1.05

2.01

0.88

-1.08

Closing cash position

3.23

1.80

1.19

1.06

1.85

0.88

-1.08

-2.39

2

Balance sheet

Au 31/12 (MEUR)

2015

2016

2017

2018

2019

2020E

2021E

2022E

Fixed assets

0.21

0.18

0.14

0.12

0.63

0.56

0.48

0.40

Intangible assets

1.26

1.11

0.90

0.72

0.72

0.59

0.45

0.31

Goodwill

3.08

3.08

3.08

3.08

3.08

3.08

3.08

3.08

Financial assets

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Inventories

0.59

1.02

0.81

0.84

0.66

0.53

0.79

0.99

Account receivables

0.94

1.41

1.38

1.32

0.95

0.90

1.34

1.68

Other receivables

0.54

0.68

0.54

0.59

0.55

0.50

0.39

0.58

Cash and cash equivalents

3.23

1.80

1.19

1.06

1.40

0.27

-1.68

-2.99

Prepaid expenses

-

-

-

-

-

-

-

-

Other non-current assets

0.06

0.13

0.12

0.13

0.12

0.12

0.12

0.12

Total assets

9.92

9.41

8.15

7.86

8.12

6.56

4.97

4.17

Equity

4.74

1.19

-0.20

-5.35

-5.57

-5.76

-6.36

-10.15

Others

-

-

-

4.86

5.78

5.78

8.15

10.68

Provisions

0.05

0.07

0.04

0.04

0.05

0.05

0.05

0.05

Financial debt

2.99

6.00

6.23

6.07

6.08

5.16

1.41

1.41

Account payables

1.10

1.19

1.04

1.16

1.04

0.68

1.01

1.27

Other debts

1.04

0.96

0.98

0.81

0.62

0.52

0.60

0.80

Deferred income and other liabilities

-

-

0.06

0.26

0.11

0.11

0.11

0.11

Total liabilities

9.92

9.41

8.15

7.86

8.12

6.56

4.97

4.17

3

IMPORTANT INFORMATION

Responsibility for this publication

This publication has been prepared under the only responsibility of BioStrategic Partners.

Recipient

This publication is exclusively designed for "Eligible Counterparties" or "Business Customers". It is not designed to be distributed or transmitted. directly or indirectly. to "Retail Customers".

Absence of investment advice

This publication has been produced for information only and does not represent investment advice. given that it has been prepared without knowledge of the financial situation. asset position or any other personal circumstance of the persons who may receive it.

Absence of buy or sell offering of financial instruments

This publication does not represent an offering or an incentive to buy or sell the financial instruments outlined in it.

Reliability of information

Every precaution has been taken by Biostrategic Partners to ensure that the information contained in this publication come from sources considered reliable. Unless otherwise specifically indicated in this publication. all opinions. estimations and forecasts given. are those of Biostrategic Partners at that date and may be revised without prior notice.

Exemption from liability

Neither Biostrategic Partners nor SwissLife Banque Privée shall be liable for any damage that may result from the incorrect or incomplete nature of this publication. Neither Biostrategic Partners or SwissLife Banque Privée is not liable for any investment decisions. regardless of their nature. made by the users of this publication on its basis.

Transfer and distribution of this publication

This document was sent. prior to its publication. to the issuer of the financial instruments to which it refers. This document may not be reproduced. distributed or published in whole or in part without the prior written consent of Biostrategic Partners and SwissLife Banque Privée.

Warning concerning performance

Investors should note that any income from financial instruments can fluctuate and that prices can fall as well as rise. Past and simulated performance does not guarantee future performance.

Detection of potential conflicts of interest

Company

Potential conflicts of interest with Biostrategic Partners

SPINEGUARD

a)

b)

c)

d)

e)

f)

g)

No

No

No

No

Yes

No

No

The analyst has a familial relationship with a founding partner of IPF Partners who holds SpineGuard' bonds with warrants attached

  1. Biostrategic Partners has participated or is participating. either as lead manager or member of an investment or guarantee syndicate for a financial transaction. either as advisor of a public offering over the last twelve months or as Listing Sponsor of the company.
  2. Biostrategic Partners holds an investment stake greater than or equal to 5% in the capital of the company under analysis.
  3. The company who is the subject of this analysis holds an investment stake greater than or equal to 5% in Biostrategic Partners.
  4. Biostrategic Partners and/or one of its affiliates is/are liquidity provider(s) or market maker(s) for (one of) the company's financial instrument/s.
  5. Biostrategic Partners has agreed with the company to provide a service of production and distribution of analysis regarding the company.
  6. Biostrategic Partners has modified its conclusions after notifying the company before its distribution of this analysis.
  7. The person/s responsible for the analysis. a director or a member of the Board of Directors of Biostrategic Partners is a manager. director or member of the Board of Directors of the company.

Company

Potential conflicts of interest with SwissLifeBanquePrivée

SPINEGUARD

a)

b)

c)

d)

e)

f)

g)

Yes

No

No

Yes

No

No

No

  1. SwissLife Banque Privée has participated or is participating. either as lead manager or member of an investment or guarantee syndicate for a financial transaction. either as advisor of a public offering over the last twelve months or as Listing Sponsor of the company.
  2. SwissLife Banque Privée holds an investment stake greater than or equal to 5% in the capital of the company under analysis.
  3. The company who is the subject of this analysis holds an investment stake greater than or equal to 5% in SwissLife Banque Privée.
  4. SwissLife Banque Privée and/or one of its affiliates is/are liquidity provider(s) or market maker(s) for (one of) the company's financial instrument/s.
  5. SwissLife Banque Privée has agreed with the company to provide a service of production and distribution of analysis regarding the company.
  6. SwissLife Banque Privée has modified its conclusions after notifying the company before its distribution of this analysis.
  7. The person/s responsible for the analysis. a director or a member of the Board of Directors of SwissLife Banque Privée is a manager. director or member of the Board of Directors of the company.

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

SpineGuard SA published this content on 16 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 October 2020 08:59:06 UTC


© Publicnow 2020
All news about SPINEGUARD
11/18SPINEGUARD : Provides Updates and Perspectives on Its ‘Safeguard' and Chap..
BU
10/20SPINEGUARD : strengthens its intellectual property with a new patent granted in ..
PU
10/20SPINEGUARD : Strengthens Its Intellectual Property With a New Patent Granted in ..
BU
10/1616 OCTOBER 2020 – 10H45 CET : SpineGuard morning note by BioStrategic Rese..
PU
10/15SPINEGUARD : reports third-quarter 2020 revenue
PU
10/15SPINEGUARD : Reports Third-quarter 2020 Revenue
BU
10/15SPINEGUARD : 3rd quarter earnings
CO
09/1616 SEPTEMBER 2020 – 10H45 CET : SpineGuard morning note by BioStrategic Re..
PU
09/15SPINEGUARD : Reports Six-Month 2020 Financial Results
PU
09/15SPINEGUARD : Reports Six-Month 2020 Financial Results
BU
More news
Financials
Sales 2019 6,83 M 8,17 M 8,17 M
Net income 2019 -0,69 M -0,82 M -0,82 M
Net Debt 2019 4,80 M 5,74 M 5,74 M
P/E ratio 2019 -3,28x
Yield 2019 -
Capitalization 3,18 M 3,80 M 3,80 M
EV / Sales 2018 1,38x
EV / Sales 2019 0,99x
Nbr of Employees 14
Free-Float 99,5%
Chart SPINEGUARD
Duration : Period :
SpineGuard Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPINEGUARD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers
NameTitle
Pierre Jérôme Chairman & Chief Executive Officer
Manuel Lanfossi Chief Financial & Administrative Officer
Thibault Chandanson Director-Research & Development
Stéphane Bette Director & Deputy Chief Executive Officer
Maurice Bourlion Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SPINEGUARD-26.45%4
MASIMO CORPORATION60.96%14 007
NOVOCURE LIMITED50.52%12 912
ASAHI INTECC CO., LTD.13.13%9 497
GETINGE AB4.05%5 806
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.37.16%4 257